Integra LifeSciences Holdings Corporation (NASDAQ:IART) Stock Has Consensus Target Price of $17.29

Shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) have received a consensus rating of “Reduce” from the eight research firms that are covering the stock, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $17.29.

Several research analysts recently issued reports on IART shares. Wall Street Zen lowered Integra LifeSciences from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. Argus upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating and set a $25.00 price objective on the stock in a report on Thursday, June 18th. UBS Group initiated coverage on Integra LifeSciences in a report on Tuesday, July 28th. They issued a “neutral” rating and a $19.00 target price on the stock. Citigroup reaffirmed a “neutral” rating and issued a $15.00 price objective (down from $19.00) on shares of Integra LifeSciences in a research report on Monday, October 5th. Finally, Wells Fargo & Company set a $15.00 price target on shares of Integra LifeSciences in a report on Saturday, October 3rd.

Institutional Investors Weigh In On Integra LifeSciences

Several institutional investors have recently bought and sold shares of the stock. Sequoia Financial Advisors LLC grew its stake in shares of Integra LifeSciences by 221.7% in the second quarter. Sequoia Financial Advisors LLC now owns 45,785 shares of the life sciences company’s stock worth $822,000 after purchasing an additional 31,552 shares during the last quarter. WINTON GROUP Ltd purchased a new position in shares of Integra LifeSciences in the 2nd quarter worth about $1,843,000. Integrated Wealth Concepts LLC purchased a new position in shares of Integra LifeSciences in the second quarter worth $84,000. Corient Private Wealth LP lifted its position in Integra LifeSciences by 66.9% during the second quarter. Corient Private Wealth LP now owns 22,749 shares of the life sciences company’s stock valued at $409,000 after purchasing an additional 9,120 shares during the period. Finally, Wellington Management Group LLP grew its position in Integra LifeSciences by 12.4% during the second quarter. Wellington Management Group LLP now owns 1,461,104 shares of the life sciences company’s stock valued at $26,241,000 after buying an additional 160,814 shares during the period. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Integra LifeSciences Price Performance

Shares of Integra LifeSciences stock traded down $0.15 during midday trading on Tuesday, hitting $13.83. 76,916 shares of the company traded hands, compared to its average volume of 899,314. The firm’s fifty day moving average price is $16.15 and its 200-day moving average price is $15.37. The stock has a market cap of $1.08 billion, a price-to-earnings ratio of -153.17, a PEG ratio of 0.69 and a beta of 1.21. The company has a debt-to-equity ratio of 1.75, a quick ratio of 2.11 and a current ratio of 3.60. Integra LifeSciences has a 12 month low of $8.70 and a 12 month high of $20.49.

Integra LifeSciences (NASDAQ:IART) last announced its quarterly earnings results on Wednesday, July 29th. The life sciences company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.08. The company had revenue of $418.76 million during the quarter, compared to analysts’ expectations of $417.54 million. Integra LifeSciences had a positive return on equity of 18.30% and a negative net margin of 0.44%. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. As a group, sell-side analysts forecast that Integra LifeSciences will post 2.45 earnings per share for the current year.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, and orthopedic procedures. Its offerings are designed to help physicians treat neurological conditions, traumatic injuries, complex wounds, and other surgical needs.

The company’s products include dural repair and regeneration materials, cerebrospinal fluid management systems, surgical instruments, nerve and tendon repair products, and tissue-engineered solutions for wound care and reconstructive surgery.